Artrya Highlights Expanding U.S. Footprint, Plaque Revenue, and FDA Submission Plans

Got story updates? Submit your updates here. ›

Artrya, an Australian medical technology company, used its latest quarterly update call to highlight an expanding U.S. commercial footprint for its Salix coronary CT angiography (CCTA) software, early plaque-related fee-per-scan revenue, and progress toward a planned FDA submission for its Coronary Flow module. The company also outlined the scope and objectives of its upcoming SAPPHIRE real-world study and reviewed a strengthened cash position following an $80 million capital raise.

Why it matters

Artrya's Salix platform, which uses AI to automate the detection of coronary artery disease from CCTA scans, represents a potentially significant advancement in cardiovascular imaging and risk assessment. The company's progress in securing U.S. commercial partners and generating early plaque-related revenue, as well as its efforts to obtain FDA clearance for the Coronary Flow module, could position Artrya as a key player in the growing field of AI-powered cardiovascular diagnostics.

The details

Artrya CEO John Konstantopoulos said the company's focus in the December quarter was on putting the 'right commercial and operational foundations in place' to support expansion in 2026. This included converting three U.S. 'foundation partners' into full commercial customers, with Salix being rolled out across Northeast Georgia's five hospitals, the Georgia Heart Institute, and Cone Health's hospitals and physician practices in North Carolina. Konstantopoulos also described the company's first Plaque fee-per-scan revenue from its integration with Tanner, with early clinician feedback being 'extremely positive.' As commercialization begins, Artrya has prioritized building an on-the-ground U.S. customer success capability, with several experienced field personnel now fully operational. The company is also finalizing onboarding of remaining Tanner centers and expects usage to move toward full volume in the next quarter and into FY2027.

• Artrya successfully integrated the Salix Coronary Plaque module and went live with Tanner at its first facility during the quarter, marking the company's 'first Plaque fee per scan revenue.'
• Artrya held a formal Q-submission meeting with the FDA during the quarter, with the FDA confirming a 510(k) approach and providing guidance on comparative data requirements and performance thresholds.
• Artrya secured all participating sites for its SAPPHIRE study ahead of launch in 2026, with Huntsville Hospital Heart Center, Mass General Brigham, Ascension Augusta, Piedmont Healthcare, HCA Healthcare, and Dignity Health (part of the CommonSpirit group) joining the study.
• Artrya expects to begin accessing retrospective scans for the SAPPHIRE study around mid-year 2026, with preliminary results expected by year-end.
• Artrya has guided that foundation customers will ramp to full volume in FY27 (roughly 15,000 scans per year) and that SAPPHIRE partners would ramp into FY28.

What they’re saying

What’s next

Artrya is finalizing onboarding of remaining Tanner centers and expects usage to move toward full volume in the next quarter and into FY2027. The company is also working to obtain FDA clearance for its Coronary Flow module by the end of June 2026.